Science News from ESC 2022
We're covering the most exciting Hot Line trials from ESC Congress 2022
This is where you will find key AHA scientific volunteers discussing the results of Tier 1 trials from Barcelona, Spain.
SECURE: A polypill strategy in secondary prevention
VIDEO: Clyde Yancy, MD, FAHA, past president of the American Heart Association, comments on the results of the SECURE trial(link opens in new window), which found that treatment with a polypill containing aspirin, an ACE inhibitor, and atorvastatin and available in multiple dosing options significantly reduced the risk of recurrent major adverse cardiovascular events in elderly patients within six months of a myocardial infarction compared to standard care.
AHA Journals Simultaneous Publications
AHA journals JAHA, Circulation, Circulation: Cardiovascular Quality and Outcomes, and Circulation: Heart Failure are publishing ESC 2022 studies as they come off embargo. Find the list here.
DANCAVAS – Screening and intervention to prevent cardiovascular disease
Investigator Alex Diederichsen, PhD recaps the results of DANCAVAS trial (published in NEJM - opens in new window)(link opens in new window), which found that after more than 5 years, the invitation to undergo comprehensive cardiovascular screening and treatment if detected did not significantly reduce the incidence of death from any cause among men 65 to 74 years of age.
Download DANCAVAS Summary Slide (PPTX)
DANFLU-1 – High-dose vs. standard-dose quadrivalent influenza vaccine in elderly adults
Investigator Tor Biering-Sørensen summarizes the results of the DANFLU-1 trial, which tested the feasibility of integrating an individually randomized trial into routine seasonal influenza vaccination practice and using the Danish administrative health registries for collection of both baseline, outcome, and safety data for the two doses (standard and high-dose) of flu vaccine in elderly adults.
REVIVED – Percutaneous Revascularisation for Ischaemic Ventricular Dysfunction
Jacqueline E. Tamis-Holland, MD, FAHA interviews investigator Divaka Perera, MA, MD, FRCP about the results of REVIVED trial, which found that PCI did not reduce the composite incidence of all-cause death or hospitalization for heart failure at a median of 3.4 years. REVIVED is published in NEJM (opens in new window).(link opens in new window)
Download REVIVED Summary Slide (PPTX)
DELIVER – Dapagliflozin in Heart Failure with Mildly Reduced and Preserved Ejection Fraction
DELIVERing Therapeutic Efficacy Across the Ejection Fraction Spectrum of Heart Failure
Carolyn S.P. Lam and Scott D. Solomon
Efficacy and Safety of Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial
Alexander Peikert, F. A. Martinez, et. al
Circulation: Heart Failure
Efficacy and Safety of Dapagliflozin According to Frailty in Patients with Heart Failure: A Prespecified Analysis of the DELIVER Trial
Jawad H. Butt, Pardeep S. Jhund, et al.
JACC: Dapagliflozin, atrial fibrillation, and heart failure with mildly reduced or preserved ejection fraction in DELIVER (link opens in new window)(link opens in new window)(link opens in new window)
Pooled Analysis: DAPA HF and DELIVER
Investigator Pardeep S. Jhund recaps the results of the Pooled Analysis of DAPA-HF and DELIVER, which found that dapagliflozin improved cardiovascular outcomes for patients with heart failure across the spectrum of ejection fraction measurement.
Pooled Analysis of DAPA HF and DELIVER Summary Slide (PPTX)
INVICTUS - Rivaroxaban versus VKA for rheumatic atrial fibrillation
ISCHEMIA-CKD EXTEND - Clinical Outcomes at 5 years of Follow-up
Investigator Sripal Bangalore, MD, MHA summarizes the results of the ISCHEMIA-CKD EXTEND trial, which found that an invasive strategy of adding cardiac catheterization and revascularization to guideline-directed medical therapy does not reduce the 5-year risk of death compared to a conservative strategy in patients with advanced CKD and chronic coronary disease.
ACT Outpatient Trial
Investigator Sanjit S. Jolly, MD, MSc, FRCPC summarizes the results of the ACT Outpatient and ACT Inpatient trials, which looked at whether anti-inflammatory and anti-coagulation therapies showed benefit for patients diagnosed with COVID-19 in outpatient and inpatient settings respectively.
MTT - Assessing the effects of ARBs and beta-blockers in Marfan Syndrome
Shaine Morris, MD, MPH interviews investigator Alex Pitcher, DPhil about the results of the MTT trial which found that treatment with either ARBs or beta-blockers delayed change in aortic root size and improved cardiovascular outcomes in patients with Marfan syndrome. The analysis further suggests that combined therapy might provide additional benefits to patients.